Ticagrelor is an oral antiplatelet drug which is used to reduce the risk of thrombotic cardiovascular events such as heart attacks and strokes in patients with acute coronary syndrome or a history of myocardial infarction. It inhibits the P2Y12 receptor, thereby preventing platelets from sticking together and forming clots. The drug is commonly prescribed after a heart attack or placement of a drug-eluting stent to reduce the chance of subsequent clots forming in patients who have increased risk for cardiovascular events. Ticagrelor has demonstrated effectiveness compared to clopidogrel in reducing cardiovascular events in multiple clinical studies.
The global ticagrelor market is estimated to be valued at US$ 1481.28 Mn in 2024 and is expected to exhibit a CAGR of 3.0% over the forecast period of 2024 to 2031.
Key Takeaways
Key players operating in the Ticagrelor Market Demand are Atlas Roofing Corporation, BASF SE, Johns Manville, Duro-Last, Inc., E. I. Du Pont De Nemours, Inc., Owens Corning, Sika AG, Standard Industries Inc., and The Dow Chemical Company.
Growing prevalence of cardiovascular diseases and increasing demand for effective antiplatelet drugs post procedures such as angioplasty and stenting are expected to create significant growth opportunities for players in the global ticagrelor market.
Key players are focusing on expanding their product portfolio andglobal footprint through partnerships and acquisitions. For instance, in 2021, The Medicines Company was acquired by Novartis to expedite development and commercialization of ticagrelor.
Market Drivers
Rising geriatric population globally which is at a higher risk of developing cardiovascular diseases is a major factor driving the ticagrelor market growth.
Growing burden of diseases like diabetes and obesity which are contributors to cardiovascular conditions is anticipated to propel the demand for antiplatelet drugs like ticagrelor over the forecast period.
Market Restraints
Stringent regulatory framework for approval of new drug applications may hamper market growth.
Bleeding risks associated with ticagrelor limits its usage in certain patient groups.
Segment Analysis
The ticagrelor market is dominated by the acute coronary syndromes (ACS) sub segment. Ticagrelor is primarily used for treating patients with ACS which includes myocardial infarction and unstable angina. According to statistics, around 6 million people suffer from ACS annually in the US alone. Ticagrelor offers improved efficacy over clopidogrel in ACS patients by reducing rate of cardiovascular events such as heart attacks and strokes. The drug significantly lowers mortality and morbidity in ACS patients undergoing Percutaneous Coronary Intervention (PCI) making it the preferred antiplatelet agent over clopidogrel in such cases. This large patient pool and enhanced efficacy over alternatives drives the growth of the ACS sub segment of the ticagrelor market.
Global Analysis
The North America region currently dominates the ticagrelor market and is expected to continue its lead during the forecast period. Higher awareness about advanced treatment options for cardiovascular conditions and large healthcare expenditure fuel the adoption of novel drugs like ticagrelor in the region. Additionally, presence of major market players in the US contributes to the large share held by North America. However, the Asia Pacific region is anticipated to showcase the fastest growth in the coming years attributed to increasing incidence of heart diseases, improving access to healthcare facilities and growing healthcare spending in developing countries of China and India. Rising medical tourism in Asia Pacific for cardiac procedures like angioplasty is further expected to drive the usage of ticagrelor in the region.
Get more insights on Ticagrelor Market
